Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics
- Under the terms of the intended acquisition:
-
- Adhera will continue clinical development of MLR-1019
-
- Melior Pharmaceuticals will receive Adhera stock plus royalties